JP2002508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508338A5
JP2002508338A5 JP2000538720A JP2000538720A JP2002508338A5 JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5 JP 2000538720 A JP2000538720 A JP 2000538720A JP 2000538720 A JP2000538720 A JP 2000538720A JP 2002508338 A5 JP2002508338 A5 JP 2002508338A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
composition according
lentivirus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000538720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/025720 external-priority patent/WO1999030742A1/en
Publication of JP2002508338A publication Critical patent/JP2002508338A/ja
Publication of JP2002508338A5 publication Critical patent/JP2002508338A5/ja
Pending legal-status Critical Current

Links

JP2000538720A 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用 Pending JP2002508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6957997P 1997-12-12 1997-12-12
US60/069,579 1997-12-12
PCT/US1998/025720 WO1999030742A1 (en) 1997-12-12 1998-12-11 Therapeutic use of lentiviral vectors

Publications (2)

Publication Number Publication Date
JP2002508338A JP2002508338A (ja) 2002-03-19
JP2002508338A5 true JP2002508338A5 (cg-RX-API-DMAC7.html) 2006-01-26

Family

ID=22089926

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000538720A Pending JP2002508338A (ja) 1997-12-12 1998-12-11 レンチウィルスベクターの治療使用

Country Status (6)

Country Link
EP (1) EP1037669A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002508338A (cg-RX-API-DMAC7.html)
KR (1) KR20010033062A (cg-RX-API-DMAC7.html)
AU (1) AU749059B2 (cg-RX-API-DMAC7.html)
CA (1) CA2314683A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999030742A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2004094642A2 (en) 2003-04-24 2004-11-04 Fondazione Centro San Raffaele Del Monte Tabor Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
WO2009049350A1 (en) 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CN108601951B (zh) 2015-12-09 2022-11-22 金港医疗(澳大利亚)私人有限公司 用于治疗的免疫调节组合物
US11285191B2 (en) 2016-07-26 2022-03-29 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Immunostimulatory compositions and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0816507A4 (en) * 1995-03-16 1998-07-01 Hisamitsu Pharmaceutical Co NEW RECOMBINANT GEN
US5650309A (en) * 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997020052A1 (en) * 1995-11-28 1997-06-05 Clinical Technologies, Inc. Recombinant hiv and modified packaging cells and method for treating acquired immune deficiency syndrome
ATE455858T1 (de) * 1995-11-28 2010-02-15 Univ Johns Hopkins Med Konditionell replizierende virale vektoren und ihre verwendung
AP964A (en) * 1996-02-21 2001-05-11 Julianna Lisziewicz Methods and compositions for protective and therapeutic genetic immunisation.
CA2247091A1 (en) * 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
WO1998003669A2 (en) * 1996-07-22 1998-01-29 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectors for inhibiting hiv and tumor growth
JP2001513643A (ja) * 1997-03-06 2001-09-04 ウーベルラ、クラウス レンチウイルスをベースとするベクター及びベクター系
GB9704977D0 (en) * 1997-03-11 1997-04-30 Univ Glasgow FIV vaccine
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors

Similar Documents

Publication Publication Date Title
EP2267452B8 (en) A soluble complex comprising a retroviral surface glycoprotein
WO1990015066A3 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in vitro des infections dues a ces virus
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
TR200001553T2 (tr) HIV-1 Tat veya bunun türevleri.
ES2113854T3 (es) Derivados de albumina con funciones terapeuticas.
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
AU3485800A (en) Inhibitors of aspartyl protease
RU96116005A (ru) Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов
WO2000061067A3 (fr) Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
NO940810L (no) Behandling av virusinfeksjoner
CA2195125A1 (en) Difluorostatone antiviral agents
BG101175A (bg) Тройна анти-нiv комбинация
JP2002523426A5 (cg-RX-API-DMAC7.html)
ATE509942T1 (de) Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren
EP1690545A3 (en) Preparation of Product R and product so obtained
FI881123L (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
DE69922642D1 (de) Virale chimären aus caev und hiv-1 genetischen elementen
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
RU2003125554A (ru) Природные антитела, активные против вируса иммунодефицита человека (вич)
WO2004041194A3 (en) Inhibition of hiv-1 replication
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
JP2007515386A5 (cg-RX-API-DMAC7.html)
FR2652091B1 (fr) Sequences nucleotidiques issues du genome des retrovirus du type hiv-1, hiv-2 et siv, et leurs applications notamment pour l'amplification des genomes de ces retrovirus et pour le diagnostic in-vitro des infections dues a ces virus.
DK0685235T3 (da) Ekstrakter af Piliostigma thonningii, anvendelse heraf og formuleringer, som indeholder dem